Infectious Diseases, Department of Molecular Medicine, University of Padua, Padua, Italy.
Infectious Diseases, Department of Mental and Physical Health, Campania University, Naples, Italy.
Int J Antimicrob Agents. 2019 Dec;54(6):697-701. doi: 10.1016/j.ijantimicag.2019.09.012. Epub 2019 Sep 18.
An estimated 20-40 million individuals worldwide are infected with hepatitis delta virus (HDV), mostly with rapidly evolving liver disease. Therapy of chronic HDV infection remains an unmet need. To date, only interferon (IFN)-based therapy is recommended for HDV infection and response rates are unsatisfactory; in addition, many patients are intolerant to or ineligible for IFN treatment. In recent years, innovative approaches have been in development, including the following: targeting virus entry into hepatocytes; inhibition of the host enzyme farnesyltransferase by prenylation inhibitors, leading to inhibition of complete virion formation and release; blockade of hepatitis B surface antigen (HBsAg) secretion, inhibiting virus release; and IFN-lambda, which causes fewer adverse effects than IFN-alfa. Clinical trials are ongoing with encouraging preliminary results.
据估计，全球有 2000 万至 4000 万人感染了乙型肝炎 delta 病毒（HDV），其中大多数人患有迅速进展的肝脏疾病。慢性 HDV 感染的治疗仍然是一个未满足的需求。迄今为止，仅推荐干扰素（IFN）治疗 HDV 感染，但反应率并不令人满意；此外，许多患者不耐受或不适合 IFN 治疗。近年来，已经开发出了一些创新方法，包括以下几种：靶向病毒进入肝细胞；通过prenylation 抑制剂抑制宿主酶法呢基转移酶，从而抑制完整病毒颗粒的形成和释放；阻断乙型肝炎表面抗原（HBsAg）的分泌，抑制病毒释放；以及 IFN-lambda，其引起的不良反应比 IFN-alfa 少。正在进行临床试验，初步结果令人鼓舞。
